Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6745045 | 1.00 | TAS1R3 (0.40) | TAS1R3TAS1R1TP53PPARGALDH1A1 | |
| SCHEMBL6744824 | 0.87 | BCHE (0.41) | TP53ALDH1A1MAPTADRA2AADRA1A | |
| SCHEMBL30669716 | 0.84 | PPARG (0.49) | TP53PPARGSMN1; SMN2TSHR | |
| SCHEMBL6055320 | 0.84 | PPARG (0.49) | TP53PPARGSMN1; SMN2TSHR | |
| Ammonia Solution, Strong SCHEMBL28835220 | 0.83 | PPARG (0.48) | TP53PPARGSMN1; SMN2TSHR | |
| SCHEMBL13570094 | 0.82 | ALDH1A1 (0.50) | TAS1R3TAS1R1ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL13263813 | 0.81 | TAS1R3 (0.40) | TAS1R3TAS1R1TP53PPARGALDH1A1 | |
| SCHEMBL20879262 | 0.81 | TAS1R3 (0.40) | TAS1R3TAS1R1TP53PPARGALDH1A1 | |
| SCHEMBL6745332 | 0.78 | MAPK1 (0.33) | TAS1R3TAS1R1PPARGALDH1A1 | |
| SCHEMBL6742914 | 0.78 | MAPK1 (0.33) | TAS1R3TAS1R1PPARGALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2374794-B1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2015-11-04 | — | — | EP | disclosed |
| EP-2374788-B1 | INDANYL COMPOUNDS | DAIICHI SANKYO CO LTD (JP) | 2013-04-03 | — | — | EP | disclosed |
| US-8183272-B2 | Indanyl compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-22 | — | — | US | disclosed |
| US-8173631-B2 | Cyclic amine compounds | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-05-08 | — | — | US | disclosed |
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| US-20110319359-A1 | INDANYL COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-12-29 | — | — | US | disclosed |
| EP-2374794-A1 | CYCLIC AMINE COMPOUNDS | Daiichi Sankyo Company, Limited (JP) | 2011-10-12 | — | — | EP | disclosed |
| WO-2010074089-A1 | INDANYL COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
| WO-2010074088-A1 | CYCLIC AMINE COMPOUNDS | 第一三共株式会社 (JP) | 2010-07-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319468-A1 | CYCLIC AMINE COMPOUNDS | RYR2, CASR, RYR1 | TAS1R3 460/4885TAS1R1 318/4885TP53 3433/4885 |
| US-20110319359-A1 | INDANYL COMPOUNDS | RYR2, ORAI1, CASR | TAS1R3 580/4885TAS1R1 393/4885TP53 2995/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.